Head-to-head · Cost-Efficiency Index
Harbor vs Kina
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Harbor
Cost-first shoppers who want price-sensitive shoppers who want a 'locked, no-increase' pricing promise on entry-tier compounded GLP-1s.
Visit HarborKina
Cost-first shoppers who want perimenopausal/menopausal women wanting GLP-1 weight management bundled with HRT and other menopause-specific care under one named clinical lead.
Visit KinaThe verdict
Harbor and Kina tie on the Cost-Efficiency Index at 69/100, so neither wins outright on the numbers. For most shoppers we'd start with Harbor (ranked #100, a hair above #103) — Cost-first shoppers who want price-sensitive shoppers who want a 'locked, no-increase' pricing promise on entry-tier compounded GLP-1s. But Kina is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Harbor.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Harbor | Kina |
|---|---|---|
| Cost-Efficiency Index | 69/100 | 69/100 |
| Semaglutide / mo | $99/mo (starting dose, compounded) | $169/mo (all doses, compounded) |
| Tirzepatide / mo | $149/mo (starting dose, compounded) | $249/mo (compounded) |
| Semaglutide / yr (modeled) | $1,188 | $2,028 |
| Tirzepatide / yr (modeled) | $1,788 | $2,988 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #100 | #103 |
Harbor
69/100Where the value is
- Among the lowest entry-tier prices seen in this set ($99 semaglutide / $149 tirzepatide)
- Explicit 'No Price Increases / Locked pricing' claim, addressing a common bait-and-switch risk
- LegitScript badge verifiably tied to the visitharbor.com domain itself
The tradeoffs
- 'As low as' framing without a visible full pricing/tier page (404'd)
- No individual is designated 'medical director' despite three physicians being pictured
Kina
69/100Where the value is
- Names an actual clinical lead (Dr. Shannon Arora, PharmD) tied to a real affiliated practice with an address
- LegitScript badge confirmed with verification link
- Consultation/physician-review fee is bundled into the price rather than charged separately
The tradeoffs
- $169 headline price is a first-month-only discount; true ongoing price is $199/mo
- Not a dedicated GLP-1 company -- weight/GLP-1 is one of six categories on a menopause-focused platform
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.